Lv1
10 积分 2023-04-12 加入
Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial
1个月前
已完结
AI-predicted spatial transcriptomics unlocks breast cancer biomarkers from pathology
4个月前
已完结
Targeted inhibition of FBXL2 confers susceptibility of HER2-negative breast cancer to trastuzumab deruxtecan
7个月前
已完结
皖公网安备34019202002308
